[go: up one dir, main page]

MX2008002492A - Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante. - Google Patents

Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.

Info

Publication number
MX2008002492A
MX2008002492A MX2008002492A MX2008002492A MX2008002492A MX 2008002492 A MX2008002492 A MX 2008002492A MX 2008002492 A MX2008002492 A MX 2008002492A MX 2008002492 A MX2008002492 A MX 2008002492A MX 2008002492 A MX2008002492 A MX 2008002492A
Authority
MX
Mexico
Prior art keywords
modifier
pharmaceutical compositions
retarding agent
dependent drug
dependent
Prior art date
Application number
MX2008002492A
Other languages
English (en)
Inventor
Andrea Kramer
Barbara Luckel
Angelika Ries
Stefanie Siepe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517204A external-priority patent/GB0517204D0/en
Priority claimed from GB0518359A external-priority patent/GB0518359D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2008002492A publication Critical patent/MX2008002492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones farmaceuticas que comprenden un compuesto de farmaco dependiente del pH, y un modificador del pH.
MX2008002492A 2005-08-22 2006-08-22 Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante. MX2008002492A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0517204A GB0517204D0 (en) 2005-08-22 2005-08-22 Organic compounds
GB0518359A GB0518359D0 (en) 2005-09-08 2005-09-08 Organic compounds
PCT/EP2006/008243 WO2007022956A2 (en) 2005-08-22 2006-08-22 Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent

Publications (1)

Publication Number Publication Date
MX2008002492A true MX2008002492A (es) 2008-04-03

Family

ID=37402546

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002492A MX2008002492A (es) 2005-08-22 2006-08-22 Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.

Country Status (11)

Country Link
US (1) US20090214645A1 (es)
EP (1) EP1919460A2 (es)
JP (2) JP2009504796A (es)
KR (1) KR20080037732A (es)
CN (1) CN102198273A (es)
AU (1) AU2006284053B2 (es)
BR (1) BRPI0614870A2 (es)
CA (1) CA2619035A1 (es)
MX (1) MX2008002492A (es)
RU (1) RU2442574C2 (es)
WO (1) WO2007022956A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2101733T3 (pl) * 2006-12-13 2013-02-28 Hoffmann La Roche Preparat w postaci proszku walgancyklowiru
EP2234963B1 (en) 2007-12-28 2020-04-08 Impax Laboratories, LLC Controlled release formulations of levodopa and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US9238571B2 (en) * 2009-09-30 2016-01-19 Merck Sharp & Dohme Limited Formulations for c-Met kinase inhibitors
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
JP6123795B2 (ja) * 2012-03-30 2017-05-10 アステラス製薬株式会社 放出制御医薬組成物
WO2015023770A1 (en) 2013-08-14 2015-02-19 Board Of Regents, The University Of Texas System Methods for fine particle manufacture
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
BR112016020738B1 (pt) * 2014-03-11 2023-04-11 Dupont Nutrition Usa, Inc Composição de liberação controlada e método
HUE047477T2 (hu) 2015-06-04 2020-04-28 Pfizer Palbociclib szilárd dózisformái
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2021161317A1 (en) * 2020-02-12 2021-08-19 Cts Chemical Industries Ltd. Stable pharmaceutical compositions comprising valgancyclovir and uses thereof
WO2022004859A1 (ja) * 2020-07-02 2022-01-06 ＡＲＴｈａｍ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 経口用医薬組成物及びその製造方法
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
US20030087913A1 (en) * 2001-10-18 2003-05-08 Schering Ag Solid pharmaceutical agent formulation for a piperazine urea derivative
RU2206316C1 (ru) * 2001-10-30 2003-06-20 Закрытое акционерное общество "ВЕРОФАРМ" Фармацевтическое средство сердечно-сосудистого действия
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20050074448A1 (en) * 2003-03-24 2005-04-07 The Curator Sof The University Of Missouri Method of treatment of endothelial dysfunction and engineered proteins for same

Also Published As

Publication number Publication date
KR20080037732A (ko) 2008-04-30
WO2007022956A3 (en) 2007-05-31
JP2009504796A (ja) 2009-02-05
EP1919460A2 (en) 2008-05-14
JP2013136637A (ja) 2013-07-11
WO2007022956A2 (en) 2007-03-01
RU2008110739A (ru) 2009-09-27
CA2619035A1 (en) 2007-03-01
CN102198273A (zh) 2011-09-28
AU2006284053B2 (en) 2010-04-22
BRPI0614870A2 (pt) 2011-04-19
US20090214645A1 (en) 2009-08-27
RU2442574C2 (ru) 2012-02-20
AU2006284053A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
WO2007019439A3 (en) Block copolymer compositions and uses thereof
NO20092611L (no) Krystallinsk faststoff Rasagilin base
TW200800999A (en) Novel compounds
IL188050A (en) The history of azaindazole, their medicinal preparations and their uses
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
AR033711A1 (es) Composiciones farmaceuticas
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TNSN08191A1 (en) Kinase inhibitors
JO2578B1 (en) Compounds Theophene benzimidazole
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
TW200731974A (en) Transdermal system for verenicline
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
IL186805A0 (en) Pharmaceutical compositions containing an active vitamin d compound
TW200621160A (en) Anti-termite agent
TW200738284A (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier
TW200700071A (en) Novel use
ZA200604874B (en) Pharmaceutical compositions
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
PL1843778T3 (pl) Kompozycje zawierające galusan epigalokatechiny i hydrolizat białkowy
TW200638932A (en) CCI-779 polymorph and use thereof
TW200503759A (en) Tablets comprising flavourings and/or aromatizing substances

Legal Events

Date Code Title Description
FG Grant or registration